Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease (original) (raw)
Inflammation and inflammatory bowel disease
Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease
- V Grossa,
- T Andusa,
- K W Eckerc,
- A Raedlerd,
- K Loeschkee,
- M Plauthf,
- J Rasenackg,
- A Weberh,
- M Gierendh,
- K Eweb,
- J Schölmericha,
- Budesonide Study Group
- aUniversity of Regensburg, bUniversity of Mainz, cUniversity of Homburg, dUniversity of Hamburg, eUniversity of München, fUniversity of Tübingen, gUniversity of Freiburg, hMedicomp, Martinsried
- Prof. J Schölmerich, Department of Internal Medicine I, University of Regensburg, D-93042 Regensburg, Germany.
Abstract
_Background_—The relapse rate after steroid induced remission in Crohn’s disease is high.
_Aims_—To test whether oral pH modified release budesonide (3 × 1 mg/day) reduces the relapse rate and to identify patient subgroups with an increased risk of relapse.
_Methods_—In a multicentre, randomised, double blind study, 179 patients with steroid induced remission of Crohn’s disease received either 3 × 1 mg budesonide (n=84) or placebo (n=95) for one year. The primary study aim was the maintenance of remission of Crohn’s disease for one year.
_Results_—Patient characteristics at study entry were similar for both groups. The relapse rate was 67% (56/84) in the budesonide group and 65% (62/95) in the placebo group. The relapse curves in both groups were similar. The mean time to relapse was 93.5 days in the budesonide group and 67.0 days in the placebo group. No prognostic factors allowing prediction of an increased risk for relapse or definition of patient subgroups who derived benefit from low dose budesonide were found. Drug related side effects were mild and no different between the budesonide and the placebo group.
_Conclusion_—Oral pH modified release budesonide at a dose of 3 × 1 mg/day is not effective for maintaining steroid induced remission in Crohn’s disease.
- budesonide
- Crohn’s disease
- maintenance of remission
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.